DK1620429T3 - Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse - Google Patents

Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse

Info

Publication number
DK1620429T3
DK1620429T3 DK04710093T DK04710093T DK1620429T3 DK 1620429 T3 DK1620429 T3 DK 1620429T3 DK 04710093 T DK04710093 T DK 04710093T DK 04710093 T DK04710093 T DK 04710093T DK 1620429 T3 DK1620429 T3 DK 1620429T3
Authority
DK
Denmark
Prior art keywords
inflammatory
preparation
treatment
methods
pharmaceutical compositions
Prior art date
Application number
DK04710093T
Other languages
Danish (da)
English (en)
Inventor
Balasubramanian Gopalan
Laxmikant Atmaram Gharat
Aftab Dawoodbhai Lakdawala
Usha Karaunakaran
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Application granted granted Critical
Publication of DK1620429T3 publication Critical patent/DK1620429T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04710093T 2003-04-11 2004-02-11 Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse DK1620429T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN363MU2003 2003-04-11
US51996703P 2003-11-13 2003-11-13
PCT/IB2004/000355 WO2004089940A1 (en) 2003-04-11 2004-02-11 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
DK1620429T3 true DK1620429T3 (da) 2009-05-18

Family

ID=36947516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04710093T DK1620429T3 (da) 2003-04-11 2004-02-11 Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse

Country Status (34)

Country Link
US (4) US7223789B2 (de)
EP (1) EP1620429B1 (de)
JP (1) JP2006522789A (de)
KR (1) KR20060017494A (de)
CN (1) CN1829711B (de)
AP (1) AP2008A (de)
AR (1) AR043199A1 (de)
AT (1) ATE427308T1 (de)
AU (1) AU2004228453B2 (de)
BR (1) BRPI0409747A (de)
CA (1) CA2522023A1 (de)
CL (1) CL2004000526A1 (de)
CO (1) CO5700824A2 (de)
DE (1) DE602004020332D1 (de)
DK (1) DK1620429T3 (de)
EA (1) EA010634B1 (de)
ES (1) ES2320888T3 (de)
GE (1) GEP20084526B (de)
HR (1) HRP20050944A2 (de)
IS (1) IS8123A (de)
MA (1) MA27801A1 (de)
MX (1) MXPA05010948A (de)
MY (1) MY136516A (de)
NO (1) NO20055316L (de)
NZ (1) NZ542882A (de)
OA (1) OA13154A (de)
PL (1) PL378813A1 (de)
PT (1) PT1620429E (de)
SI (1) SI1620429T1 (de)
TN (1) TNSN05252A1 (de)
TW (1) TW200508212A (de)
UA (1) UA79558C2 (de)
WO (1) WO2004089940A1 (de)
ZA (1) ZA200508240B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010408B1 (ru) * 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
OA13154A (en) * 2003-04-11 2006-12-13 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them.
EP1799632A2 (de) 2004-10-13 2007-06-27 Glenmark Pharmaceuticals S.A. Verfahren zúr herstellung von n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methansulfonamido-dibenzo[b,d]furan-1-carboxamid
WO2006051390A1 (en) * 2004-11-10 2006-05-18 Glenmark Pharmaceuticals S.A. Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, pharmaceutical compositions containing them, and methods of preparing them
CN101124229B (zh) * 2004-12-17 2012-07-18 格兰马克药品股份有限公司 用于治疗炎性和过敏性障碍的新杂环化合物
AP2334A (en) * 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2359826B1 (de) 2006-07-05 2013-10-30 Takeda GmbH Kombination des HMG-CoA -Reduktase-Inhibitors Rosuvastatin mit einem Phosphodiesterase-4-Inhibitor, wie z.B Roflumilast, Roflumilast-N-Oxide, zur Behandlung von entzündlichen Lungenerkrankungen
US7511150B2 (en) * 2006-07-06 2009-03-31 Forest Laboratories Holdings Limited Synthesis of heterocyclic compounds
JPWO2008026687A1 (ja) * 2006-09-01 2010-01-21 杏林製薬株式会社 ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
US20090318385A1 (en) * 2006-09-06 2009-12-24 Yasushi Kohno Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient
AU2007297221B2 (en) * 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
WO2008057254A2 (en) * 2006-10-27 2008-05-15 Wyeth Tricyclic compounds as matrix metalloproteinase inhibitors
WO2008065522A2 (en) * 2006-11-29 2008-06-05 Glenmark Pharmaceuticals S.A. Process for the synthesis of 4-difluoromethoxy-8-nitro-1-formyl dibenzo[b,d] furan-an intermediate for pde iv inhibitors
US20100098641A1 (en) * 2006-12-13 2010-04-22 William Baker Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
MX2009008463A (es) * 2007-02-09 2010-01-27 Forest Lab Holdings Ltd Formulaciones biodisponibles de compuestos heterociclicos.
US8524905B2 (en) 2007-05-22 2013-09-03 Glenmark Pharmaceuticals S.A. Processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-9-carbaldehyde, a novel intermediate for the synthesis of PDE IV inhibitors
WO2008157205A2 (en) * 2007-06-15 2008-12-24 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
EP2070913A1 (de) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester-Derivate als Phosphodiesterase-Hemmer
WO2009147476A1 (en) * 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
TWI474282B (zh) * 2008-10-03 2015-02-21 Himax Tech Ltd 深度相關的影像加強
JP5487214B2 (ja) 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
WO2011132051A2 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
WO2012079172A1 (en) * 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
WO2014133020A1 (ja) * 2013-02-28 2014-09-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 呼吸器疾患の予防治療剤
CN104177612A (zh) * 2013-05-28 2014-12-03 韩文毅 一种新的非线性聚合物及其制备和用途
CN104211947A (zh) * 2013-05-31 2014-12-17 韩文毅 一种非线性聚合物及其制备和用途
CN104211950A (zh) * 2013-06-04 2014-12-17 韩文毅 一种非线性聚合物及其制备与用途
CN104211949A (zh) * 2013-06-04 2014-12-17 韩文毅 一种非线性聚合物及其制备与用途
EP3365340B1 (de) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclische verbindungen als immunmodulatoren
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
RU2616617C1 (ru) * 2016-04-12 2017-04-18 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук 5-(9-этил-9Н-карбазол-3-ил)-4-[5-(9-этил-9Н-карбазол-3-ил)-тиофен-2-ил]-пиримидин
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN109651232A (zh) * 2018-12-12 2019-04-19 河北华清光电材料有限公司 制备4-溴咔唑及其衍生物的方法
EP4010342A1 (de) 2019-08-09 2022-06-15 Incyte Corporation Salze eines pd-1/pd-l1-inhibitors
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN114163417B (zh) * 2021-12-06 2023-08-04 郑州海阔光电材料有限公司 一种3-溴硫芴的合成方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041861A (en) 1962-03-14 1966-09-07 Organon Labor Ltd Pyrrolidone derivatives and pharmaceutical preparations containing them
US3759948A (en) * 1969-06-25 1973-09-18 Merck & Co Inc Non-steroid anti-inflammatory compounds
NL7008628A (de) * 1969-06-25 1970-12-29
NL7016899A (de) 1969-12-03 1971-06-07
US3846553A (en) * 1969-12-03 1974-11-05 Merck & Co Inc 3-substituted-2-pyridones in the treatment of pain, fever or inflammation
US4222944A (en) * 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
JPS62158253A (ja) 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
JPH0812430B2 (ja) 1986-07-07 1996-02-07 キヤノン株式会社 電子写真感光体
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
MX9301903A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
MX9306311A (es) * 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
WO1995009837A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Cyano compounds
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
MX9700696A (es) 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos
DK1064298T3 (da) 1998-03-19 2009-01-19 Vertex Pharma Inhibitorer af caspaser
JP2002514638A (ja) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性および高血糖症の治療に有用な１１−アリール−ベンゾ［ｂ］ナフト［２，３−ｄ］フラン類および１１−アリール−ベンゾ［ｂ］ナフト［２，３−ｄ］チオフェン類
US6110962A (en) * 1998-05-12 2000-08-29 American Home Products Corporation 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
JP2003528072A (ja) 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー マトリックスメタロプロテアーゼおよびＴＮＦ−αの阻害剤としての環状β−アミノ酸誘導体
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
KR20090090406A (ko) * 2000-12-18 2009-08-25 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 염증성 사이토카인 생산 유리 억제제
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
AU2002306687A1 (en) 2001-03-13 2002-09-24 Glenmark Pharmaceuticals Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
US7378428B2 (en) * 2002-01-31 2008-05-27 Ono Pharmaceutical Co., Ltd. Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EA010408B1 (ru) * 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
OA13154A (en) * 2003-04-11 2006-12-13 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them.
CN101124229B (zh) * 2004-12-17 2012-07-18 格兰马克药品股份有限公司 用于治疗炎性和过敏性障碍的新杂环化合物

Also Published As

Publication number Publication date
KR20060017494A (ko) 2006-02-23
AU2004228453A1 (en) 2004-10-21
TW200508212A (en) 2005-03-01
WO2004089940A1 (en) 2004-10-21
EP1620429B1 (de) 2009-04-01
ATE427308T1 (de) 2009-04-15
MA27801A1 (fr) 2006-03-01
GEP20084526B (en) 2008-11-10
IS8123A (is) 2005-11-10
AP2008A (en) 2009-06-29
DE602004020332D1 (de) 2009-05-14
NO20055316L (no) 2006-01-11
EA200501617A1 (ru) 2006-04-28
ES2320888T3 (es) 2009-05-29
MY136516A (en) 2008-10-31
US20050027129A1 (en) 2005-02-03
BRPI0409747A (pt) 2006-05-09
NO20055316D0 (no) 2005-11-10
ZA200508240B (en) 2006-05-31
TNSN05252A1 (en) 2007-07-10
OA13154A (en) 2006-12-13
US20070105854A1 (en) 2007-05-10
AR043199A1 (es) 2005-07-20
MXPA05010948A (es) 2006-05-31
UA79558C2 (en) 2007-06-25
US7384962B2 (en) 2008-06-10
AU2004228453B2 (en) 2010-08-19
US7393846B2 (en) 2008-07-01
US7223789B2 (en) 2007-05-29
CO5700824A2 (es) 2006-11-30
HRP20050944A2 (en) 2006-02-28
PT1620429E (pt) 2009-04-28
CN1829711A (zh) 2006-09-06
CN1829711B (zh) 2010-06-16
EA010634B1 (ru) 2008-10-30
CL2004000526A1 (es) 2005-03-18
US20090182143A1 (en) 2009-07-16
SI1620429T1 (sl) 2009-08-31
JP2006522789A (ja) 2006-10-05
EP1620429A1 (de) 2006-02-01
US20070105855A1 (en) 2007-05-10
AP2005003424A0 (en) 2005-12-31
NZ542882A (en) 2007-10-26
CA2522023A1 (en) 2004-10-21
PL378813A1 (pl) 2006-05-29

Similar Documents

Publication Publication Date Title
DK1620429T3 (da) Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
IS7552A (is) Bensótengdar heteróarýl amíð afleiður af þíenópýridíni, gagnlegar sem meðferðarmiðlar, lyfjasamsetningar sem innihalda þær og aðferðir við notkun þeirra
DK1928886T3 (da) Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1698630T3 (da) Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
DK2069342T3 (da) Derivater af 2-aryl-6-phenyl-imidazol[1,2-A]pyridiner, fremstilling og terapeutisk anvendelse deraf
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
DK1673104T4 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
NO332405B1 (no) Forbindelse av 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling, deres anvendelse til fremstilling av farmasoytiske midler for behandling av inflammatorisk sykdom og farmasoytisk preparat omfattende forbindelsen.
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
IS7859A (is) Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
DK1575951T3 (da) Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
DK1765376T3 (da) Topiske sammensætninger og anvendelse deraf til behandling af epitel-relaterede tilstande
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner